A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Key Inclusion Criteria (Part 1 and Part 2): * Confirmed relapsed or refractory MM (measurable disease) or PCL. * Prior treatment regimens for Part 1: Patients should have received at least 2 prior treatment regimens. Prior treatment must have included at least one full cycle of a proteasome inhibitor (e.g., bortezomib or carfilzomib) and at least one full cycle of an IMiD (e.g., thalidomide, lenalidomide or pomalidomide). * Prior treatment regimens for Part 2: Patients should have received 1 to 3 prior treatment regimens. Prior treatment could have included bortezomib only if the disease was not refractory to treatment with bortezomib (refractory defined as documented progression on therapy or within 60 days of completing treatment with bortezomib). * The disease should have progressed per IMWG criteria during or after the last prior treatment regimen. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. * Adequate hematology laboratory values without transfusion support and without hematological growth factor support within 2 weeks of screening. * Adequate liver and renal function. * Additional criteria exist. Key Exclusion Criteria (Part 1 and Part 2): * Primary amyloidosis. * Peripheral neuropathy ≥ Grade 2 or neuropathy with pain, regardless of grade. * Concomitant malignancies or previous malignancies with less than a 3-year disease free interval at the time of enrollment (patients with adequately resected basal or squamous cell carcinoma of …